Surmodics, Inc. (SRDX) Bundle
An Overview of Surmodics, Inc. (SRDX)
General Summary of Surmodics, Inc. (SRDX)
Surmodics, Inc. is a leading provider of medical device and in vitro diagnostic technologies, headquartered in Eden Prairie, Minnesota. Founded in 1979, the company has evolved significantly over the decades, focusing on innovation in the healthcare sector. Surmodics specializes in developing and commercializing products designed to enhance the performance of medical devices and diagnostics, particularly in areas such as vascular intervention and surface modification.
As of 2024, Surmodics offers an array of products, including the SurVeil™ drug-coated balloon and the Pounce™ thrombectomy system. The company has reported total revenue of $126.1 million for the fiscal year ending September 30, 2024, which reflects a decrease from $132.6 million in the previous year primarily due to the absence of substantial license fee revenue associated with the SurVeil DCB.
Company's Financial Performance in the Latest Financial Reports
In the fourth quarter of fiscal 2024, Surmodics reported total revenue of $33.2 million, marking a 19% increase year-over-year. Excluding revenue from the SurVeil DCB license fees, revenue reached $31.3 million, which is a 17% increase compared to the same quarter in the previous year.
For the fiscal year 2024, the breakdown of revenue is as follows:
| Segment | Revenue (in thousands) | Year-over-Year Change |
|---|---|---|
| Medical Device | $97,508 | (8)% |
| In Vitro Diagnostics | $28,570 | 7% |
| Total | $126,078 | (5)% |
The company reported a GAAP net loss of $(11.5) million or $(0.82) per diluted share for the fiscal year. Adjusted EBITDA decreased to $14.7 million from $21.5 million in the prior year. The decline in net income is attributed to increased operating costs and the absence of large milestone payments seen in prior fiscal periods.
Introduction to Surmodics as an Industry Leader
Surmodics, Inc. stands as a prominent figure in the medical device industry, recognized for its innovative solutions that significantly improve patient outcomes. The company has established itself as a key player, particularly in the vascular intervention market, owing to its cutting-edge products like the Pounce thrombectomy system and the SurVeil DCB.
With a commitment to advancing healthcare technology, Surmodics has garnered a strong reputation for quality and reliability. The anticipated acquisition by GTCR, valued at approximately $627 million, is expected to further bolster its strategic initiatives and market position. To understand the full scope of Surmodics' impact and its future prospects, readers are encouraged to explore the company's developments in greater detail below.
Mission Statement of Surmodics, Inc. (SRDX)
Company's Mission Statement Overview
Surmodics, Inc. (SRDX) is committed to advancing healthcare by providing innovative medical device and in vitro diagnostic solutions. The mission statement reflects the company's dedication to enhancing patient outcomes through high-quality products and services, aligning with its long-term strategic goals.
Core Component 1: Innovation
Innovation is at the heart of Surmodics' mission. The company focuses on developing new technologies that improve patient care and clinical outcomes. For instance, the recent introduction of the Pounce™ XL Thrombectomy System, which received FDA 510(k) clearance on October 1, 2024, exemplifies Surmodics' commitment to innovation in medical devices.
In fiscal year 2024, Surmodics reported a total revenue of $126.1 million, with significant contributions from its Medical Device segment, which generated $97.5 million. This revenue reflects a strategic emphasis on innovative products, driving a 22% increase in Medical Device revenue during the fourth quarter compared to the previous year.
Core Component 2: Quality
Quality assurance is a fundamental aspect of Surmodics' mission statement. The company adheres to rigorous standards in product development and manufacturing. For example, Surmodics' product gross margin improved to 54.6% in the fourth quarter of fiscal 2024, indicating enhanced production efficiency and quality control.
Surmodics' performance in the Medical Device sector, particularly with its SurVeil drug-coated balloon (DCB) product, demonstrates its commitment to quality. The company achieved product sales of $11.8 million within this segment during the fourth quarter, reflecting a 39% increase year-over-year.
Core Component 3: Customer Focus
Customer focus is a critical element of Surmodics' mission. The company strives to meet the needs of healthcare providers and patients by delivering tailored solutions. This is evident in the growth of its In Vitro Diagnostics (IVD) segment, which saw an increase in revenue to $28.6 million in fiscal 2024, up 7% from the prior year.
Surmodics' total revenue for the fourth quarter of fiscal 2024 reached $33.2 million, marking a 19% increase from $27.9 million in the same quarter of fiscal 2023. This growth reflects not only the company's innovative product offerings but also its responsiveness to customer demands.
| Financial Metric | FY 2024 | FY 2023 | Change (%) |
|---|---|---|---|
| Total Revenue | $126.1 million | $132.6 million | -5% |
| Medical Device Revenue | $97.5 million | $105.8 million | -8% |
| In Vitro Diagnostics Revenue | $28.6 million | $26.8 million | +7% |
| GAAP Net Loss | $(11.5) million | $(1.5) million | N/A |
| Adjusted EBITDA | $14.7 million | $21.5 million | -31.9% |
Vision Statement of Surmodics, Inc. (SRDX)
Vision for Innovation in Medical Devices
The vision of Surmodics, Inc. (SRDX) as of 2024 emphasizes its commitment to leading innovation in medical devices. The company aims to enhance patient outcomes through advanced technologies and solutions in vascular intervention and in vitro diagnostics.
Focus on Patient-Centered Solutions
Surmodics envisions delivering patient-centered solutions that improve the quality of care. This includes the development of products like the Pounce™ XL Thrombectomy System, which received FDA clearance in October 2024. This system targets larger peripheral arteries, expanding the clinical utility of the Pounce platform.
Commitment to Sustainable Growth
Surmodics is dedicated to sustainable growth, reflected in its strategic initiatives and financial performance. In fiscal 2024, the company reported total revenue of $126.1 million, a decrease from $132.6 million in the previous year. However, excluding SurVeil DCB license fee revenue, total revenue increased by 17% year-over-year to $121.0 million.
| Financial Metric | Fiscal Year 2024 | Fiscal Year 2023 | Year-Over-Year Change |
|---|---|---|---|
| Total Revenue | $126.1 million | $132.6 million | -5% |
| Total Revenue (excl. SurVeil DCB) | $121.0 million | $103.0 million | +17% |
| GAAP Net Loss | $(11.5) million | $(1.5) million | -667% |
| Adjusted EBITDA | $14.7 million | $21.5 million | -32.5% |
Strategic Partnerships and Collaborations
The company continues to strengthen its position through strategic partnerships. The exclusive distribution agreement with Abbott for the SurVeil DCB has been pivotal in driving revenue growth. In fiscal 2024, Surmodics’ medical device revenue was primarily derived from product sales, which increased by 34% year-over-year to $45.6 million.
Vision for Regulatory Excellence
Surmodics aims for excellence in regulatory compliance and responsiveness, which is critical for maintaining its market position. The company is currently navigating the regulatory landscape related to its pending acquisition by GTCR, which is expected to close in the second fiscal quarter of 2025. This acquisition, valued at approximately $627 million, highlights Surmodics' strategic direction and growth potential.
Future Outlook and Market Positioning
Looking ahead, Surmodics envisions expanding its market presence through continuous innovation and improved operational efficiencies. The company is enhancing its product offerings, aiming to capture a larger share of the medical device market, particularly in vascular interventions.
Core Values of Surmodics, Inc. (SRDX)
Integrity
The core value of Integrity at Surmodics, Inc. emphasizes ethical conduct and transparency in all business dealings. This principle is crucial for maintaining trust with stakeholders, including customers, employees, and investors.
In 2024, Surmodics demonstrated its commitment to integrity by adhering to strict regulatory standards during its merger with GTCR LLC. The company proactively engaged with the U.S. Federal Trade Commission (FTC) to ensure compliance, receiving a "Second Request" for additional information, which they addressed promptly to facilitate the acquisition process.
Innovation
Innovation is a cornerstone of Surmodics’ strategy, driving advancements in medical device and diagnostic technologies. The company invests significantly in research and development to enhance its product offerings.
For fiscal year 2024, Surmodics reported R&D expenditures of approximately $38.4 million, maintaining a focus on developing technologies such as the Pounce Thrombectomy System, which received FDA 510(k) clearance. This innovation led to a 34% increase in product sales within the medical device segment, totaling $45.6 million.
Collaboration
Collaboration is vital for Surmodics as it fosters teamwork both internally and externally with partners. The company works closely with healthcare providers and industry partners to develop effective solutions.
In 2024, Surmodics collaborated with Abbott Vascular, which significantly boosted sales of the SurVeil DCB. This partnership resulted in a remarkable 39% increase in product sales for the thrombectomy device platform. Additionally, the company's performance coating royalties increased by 14%, driven by collaborative efforts with various clients.
Excellence
The value of Excellence reflects Surmodics' commitment to high standards in product quality and customer service. This is fundamental to their reputation in the healthcare industry.
Surmodics achieved a product gross margin of 54.6% in the fourth quarter of fiscal 2024, up from 54.2% in the prior year, showcasing operational excellence. The company’s focus on quality is further evidenced by the positive outcomes reported from its PROWL registry study, which indicated a 96.8% procedural flow restoration rate using the Pounce Thrombectomy System.
Accountability
Accountability ensures that all employees at Surmodics take responsibility for their actions and decisions. This value is essential for building a culture of trust and reliability.
In 2024, Surmodics faced challenges, including a GAAP net loss of $(11.5) million for the fiscal year. Despite this, the company maintained transparency with stakeholders about its financial performance and the impacts of its strategic decisions, which included incurring $3.7 million in merger-related charges.
| Core Value | Description | 2024 Highlights |
|---|---|---|
| Integrity | Commitment to ethical conduct and transparency | Engaged with FTC for compliance during GTCR merger |
| Innovation | Focus on R&D for new technologies | R&D expenditures of $38.4 million; FDA clearance for new devices |
| Collaboration | Working with partners to enhance solutions | 39% increase in sales from partnership with Abbott |
| Excellence | High standards in product quality and service | Product gross margin of 54.6%; successful clinical outcomes |
| Accountability | Responsibility for actions and decisions | Maintained transparency despite a net loss of $(11.5) million |
Surmodics, Inc. (SRDX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Surmodics, Inc. (SRDX) Financial Statements – Access the full quarterly financial statements for Q4 2024 to get an in-depth view of Surmodics, Inc. (SRDX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Surmodics, Inc. (SRDX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.